|
Category: natural substances and extractives
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white needles (est) |
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 86.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 380.29 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 357.00 °F. TCC ( 180.30 °C. ) (est)
|
| logP (o/w): | -0.700 |
| Soluble in: |
| | water, 1e+006 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LD50 7 mg/kg CARDIAC: OTHER CHANGES Indian Veterinary Journal. Vol. 57, Pg. 31, 1980.
intraperitoneal-guinea pig LD50 5 mg/kg "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 736, 1948.
intravenous-guinea pig LD50 180 ug/kg Journal of Pharmacology and Experimental Therapeutics. Vol. 95, Pg. 45, 1949.
oral-guinea pig LDLo 200 mg/kg LUNGS, THORAX, OR RESPIRATION: DYSPNEA "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 718, 1948.
intraperitoneal-mouse LD50 725 mg/kg British Journal of Pharmacology and Chemotherapy. Vol. 17, Pg. 137, 1961.
intravenous-mouse LD50 385 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: ATAXIA
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 89, 1979.
oral-mouse LD50 220 mg/kg Japanese Journal of Toxicology. Vol. 4, Pg. 105, 1991.
intravenous-rabbit LDLo 2 mg/kg "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 784, 1948.
intravenous-rat LD50 630 mg/kg LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
LUNGS, THORAX, OR RESPIRATION: DYSPNEA Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 89, 1979.
|
| Dermal Toxicity: |
subcutaneous-cat LDLo 34 mg/kg Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 185, Pg. 461, 1937.
subcutaneous-dog LDLo 28500 ug/kg GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
BEHAVIORAL: COMA "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 718, 1948.
subcutaneous-frog LDLo 1700 mg/kg "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 718, 1948.
subcutaneous-guinea pig LDLo 8 mg/kg Farmaco, Edizione Scientifica. Vol. 9, Pg. 379, 1954.
subcutaneous-mouse LD50 2500 mg/kg BEHAVIORAL: ATAXIA
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 89, 1979.
subcutaneous-rabbit LDLo 12 mg/kg CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 718, 1948.
subcutaneous-rat LDLo 250 mg/kg AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 185, Pg. 461, 1937.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | natural substances and extractives |
| Recommendation for histamine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for histamine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| European Food Safety Authority (EFSA) reference(s): |
Scientific Report of EFSA on the risk assessment of salts of authorised acids, phenols or alcohols for use in food contact materials [1] View page or View pdf |
Assessment of the incidents of histamine intoxication in some EU countries View page or View pdf |
| EPI System: | View |
| ClinicalTrials.gov: | search |
| Daily Med: | search |
| Chemical Carcinogenesis Research Information System: | Search |
| AIDS Citations: | Search |
| Cancer Citations: | Search |
| Toxicology Citations: | Search |
| EPA Substance Registry Services (TSCA): | 51-45-6 |
| EPA ACToR: | Toxicology Data |
| EPA Substance Registry Services (SRS): | Registry |
| Laboratory Chemical Safety Summary : | 774 |
| National Institute of Allergy and Infectious Diseases: | Data |
| WGK Germany: | 3 |
| | 2-(1H-imidazol-5-yl)ethanamine |
| Chemidplus: | 0000051456 |
| RTECS: | MS1050000 for cas# 51-45-6 |
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 4-(2- | aminoethyl)-1H-imidazole | | beta- | aminoethylglyoxaline | | beta- | aminoethylimidazole | | | ergamine | | | ergotidine | | | ethylamine, 2-imidazol-4-yl- | | 2- | imidazol-4-yl ethyl amine | | 2- | imidazol-4-yl ethylamine | | 2-(1H- | imidazol-5-yl)ethanamine | | 1H- | imidazole-4-ethanamine | | | imidazole, 4-(2-aminoethyl)- | | 5- | imidazoleethylamine | | beta- | imidazolyl-4-ethylamine | | 2-(4- | imidazolyl)ethylamine | | | istamina | | | theramine |
Articles:
|